Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Spatiotemporal variation in mechanisms driving regional-scale population dynamics of a Threatened grassland bird.

Ethier DM, Koper N, Nudds TD.

Ecol Evol. 2017 Apr 27;7(12):4152-4162. doi: 10.1002/ece3.3004. eCollection 2017 Jun.

2.

Spatial patterns of immunogenetic and neutral variation underscore the conservation value of small, isolated American badger populations.

Rico Y, Ethier DM, Davy CM, Sayers J, Weir RD, Swanson BJ, Nocera JJ, Kyle CJ.

Evol Appl. 2016 Aug 21;9(10):1271-1284. eCollection 2016 Dec.

3.

THE OCCURRENCE OF PATHOGENS IN AN ENDANGERED POPULATION OF AMERICAN BADGERS (TAXIDEA TAXUS JACKSONI) IN ONTARIO, CANADA.

Ethier DM, Sayers JB, Kyle CJ, Nocera JJ, Ojkic D, Campbell D.

J Wildl Dis. 2017 Jan;53(1):73-80. doi: 10.7589/2016-02-040. Epub 2016 Oct 17.

PMID:
27749192
4.

Tracking animal movement by comparing trace element signatures in claws to spatial variability of elements in soils.

Ethier DM, Kyle CJ, Nocera JJ.

Sci Total Environ. 2014 Jan 15;468-469:699-705. doi: 10.1016/j.scitotenv.2013.08.091. Epub 2013 Sep 21.

PMID:
24061061
5.

Trisubstituted ureas as potent and selective mPGES-1 inhibitors.

Chiasson JF, Boulet L, Brideau C, Chau A, Claveau D, Côté B, Ethier D, Giroux A, Guay J, Guiral S, Mancini J, Massé F, Méthot N, Riendeau D, Roy P, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1488-92. doi: 10.1016/j.bmcl.2011.01.006. Epub 2011 Jan 13.

PMID:
21295979
6.

Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors.

Giroux A, Boulet L, Brideau C, Chau A, Claveau D, Côté B, Ethier D, Frenette R, Gagnon M, Guay J, Guiral S, Mancini J, Martins E, Massé F, Méthot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5837-41. doi: 10.1016/j.bmcl.2009.08.085. Epub 2009 Aug 28.

PMID:
19748780
7.

Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C.

Guay D, Beaulieu C, Truchon JF, Jagadeeswar Reddy T, Zamboni R, Bayly CI, Methot N, Rubin J, Ethier D, David Percival M.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5392-6. doi: 10.1016/j.bmcl.2009.07.114. Epub 2009 Jul 28. Erratum in: Bioorg Med Chem Lett. 2009 Nov 15;19(22):6481. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1463. Truchon, Jean-Francois [added]; Bayly, Christopher I [added].

PMID:
19665376
8.

In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C.

Méthot N, Guay D, Rubin J, Ethier D, Ortega K, Wong S, Normandin D, Beaulieu C, Reddy TJ, Riendeau D, Percival MD.

Mol Pharmacol. 2008 Jun;73(6):1857-65. doi: 10.1124/mol.108.045682. Epub 2008 Mar 6.

PMID:
18326050
9.

Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.

Côté B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, Mancini J, Martins E, Massé F, Méthot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6816-20. Epub 2007 Oct 17.

PMID:
18029174
10.

Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.

Méthot N, Rubin J, Guay D, Beaulieu C, Ethier D, Reddy TJ, Riendeau D, Percival MD.

J Biol Chem. 2007 Jul 20;282(29):20836-46. Epub 2007 May 29.

11.

Substituted coumarins as potent 5-lipoxygenase inhibitors.

Grimm EL, Brideau C, Chauret N, Chan CC, Delorme D, Ducharme Y, Ethier D, Falgueyret JP, Friesen RW, Guay J, Hamel P, Riendeau D, Soucy-Breau C, Tagari P, Girard Y.

Bioorg Med Chem Lett. 2006 May 1;16(9):2528-31. Epub 2006 Feb 7.

PMID:
16464579
12.

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Macdonald D, Mastracchio A, Perrier H, Dubé D, Gallant M, Lacombe P, Deschênes D, Roy B, Scheigetz J, Bateman K, Li C, Trimble LA, Day S, Chauret N, Nicoll-Griffith DA, Silva JM, Huang Z, Laliberté F, Liu S, Ethier D, Pon D, Muise E, Boulet L, Chan CC, Styhler A, Charleson S, Mancini J, Masson P, Claveau D, Nicholson D, Turner M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. Epub 2005 Sep 15.

PMID:
16168647
13.

An automated multistep high-throughput screening assay for the identification of lead inhibitors of the inducible enzyme mPGES-1.

Massé F, Guiral S, Fortin LJ, Cauchon E, Ethier D, Guay J, Brideau C.

J Biomol Screen. 2005 Sep;10(6):599-605. Epub 2005 Aug 15.

PMID:
16103419
14.

Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886.

Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, Guiral S, Juteau H, Mancini JA, Méthot N, Rubin J, Friesen RW.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3352-5.

PMID:
15953724
15.

5-oxo-6,8,11,14-eicosatetraenoic acid stimulates the release of the eosinophil survival factor granulocyte/macrophage colony-stimulating factor from monocytes.

Stamatiou PB, Chan CC, Monneret G, Ethier D, Rokach J, Powell WS.

J Biol Chem. 2004 Jul 2;279(27):28159-64. Epub 2004 May 10.

16.

Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile.

Boulet L, Ouellet M, Bateman KP, Ethier D, Percival MD, Riendeau D, Mancini JA, Méthot N.

J Biol Chem. 2004 May 28;279(22):23229-37. Epub 2004 Mar 11.

17.

Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.

Ducharme Y, Friesen RW, Blouin M, Côté B, Dubé D, Ethier D, Frenette R, Laliberté F, Mancini JA, Masson P, Styhler A, Young RN, Girard Y.

Bioorg Med Chem Lett. 2003 Jun 2;13(11):1923-6.

PMID:
12749899
18.

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC.

J Pharmacol Exp Ther. 2001 Feb;296(2):558-66.

PMID:
11160644
19.

Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.

Lau CK, Brideau C, Chan CC, Charleson S, Cromlish WA, Ethier D, Gauthier JY, Gordon R, Guay J, Kargman S, Li CS, Prasit P, Riendeau D, Thérien M, Visco DM, Xu L.

Bioorg Med Chem Lett. 1999 Nov 15;9(22):3187-92.

PMID:
10576685
20.

Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.

Frenette R, Hutchinson JH, Léger S, Thérien M, Brideau C, Chan CC, Charleson S, Ethier D, Guay J, Jones TR, McAuliffe M, Piechuta H, Riendeau D, Tagari P, Girard Y.

Bioorg Med Chem Lett. 1999 Aug 16;9(16):2391-6.

PMID:
10476875
21.

Vanadate inhibition of protein tyrosine phosphatases in Jurkat cells: modulation by redox state.

Cuncic C, Detich N, Ethier D, Tracey AS, Gresser MJ, Ramachandran C.

J Biol Inorg Chem. 1999 Jun;4(3):354-9.

PMID:
10439081
22.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al.

J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

PMID:
10411562
23.

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8.

PMID:
10406640
24.

2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.

Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, Hughes G, Jolicoeur P, Leblanc Y, Nicoll-Griffith D, Ouimet N, Riendeau D, Visco D, Wang Z, Xu L, Prasit P.

J Med Chem. 1999 Apr 8;42(7):1274-81.

PMID:
10197970
25.

2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.

Friesen RW, Brideau C, Chan CC, Charleson S, Deschênes D, Dubé D, Ethier D, Fortin R, Gauthier JY, Girard Y, Gordon R, Greig GM, Riendeau D, Savoie C, Wang Z, Wong E, Visco D, Xu LJ, Young RN.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2777-82.

PMID:
9873621
26.

Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530.

Dubé D, Blouin M, Brideau C, Chan CC, Desmarais S, Ethier D, Falgueyret JP, Friesen RW, Girard M, Girard Y, Guay J, Riendeau D, Tagari P, Young RN.

Bioorg Med Chem Lett. 1998 May 19;8(10):1255-60.

PMID:
9871745
27.

Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.

Hamel P, Riendeau D, Brideau C, Chan CC, Desmarais S, Delorme D, Dubé D, Ducharme Y, Ethier D, Grimm E, Falgueyret JP, Guay J, Jones TR, Kwong E, McAuliffe M, McFarlane CS, Piechuta H, Roumi M, Tagari P, Young RN, Girard Y.

J Med Chem. 1997 Aug 29;40(18):2866-75.

PMID:
9288168
28.

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al.

Br J Pharmacol. 1997 May;121(1):105-17.

29.

Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells.

Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA, O'Neill GP.

Biochem Pharmacol. 1996 Oct 11;52(7):1113-25.

PMID:
8831731
30.

The influence of anulotomy selection on disc competence. A radiographic, biomechanical, and histologic analysis.

Ethier DB, Cain JE, Yaszemski MJ, Glover JM, Klucznik RP, Pyka RE, Lauerman WC.

Spine (Phila Pa 1976). 1994 Sep 15;19(18):2071-6.

PMID:
7825048
31.

5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.

Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, Heibein JA, Charleson S, Singer II.

J Exp Med. 1993 Dec 1;178(6):1935-46.

32.

Spine injuries in combat troops--Panama, 1989.

Parsons TW 3rd, Lauerman WC, Ethier DB, Gormley W, Cain JE, Elias Z, Coe J.

Mil Med. 1993 Jul;158(7):501-2.

PMID:
8351057
33.

Further studies on the adjuvanticity of stearyl tyrosine and ester analogues.

Penney CL, Ethier D, Dionne G, Nixon-George A, Zaghouani H, Michon F, Jennings H, Bona CA.

Vaccine. 1993;11(11):1129-34.

PMID:
8249432
34.

Characterization of monoclonal antibodies against human leukocyte 5-lipoxygenase.

Ethier D, Evans JF.

Prostaglandins Leukot Essent Fatty Acids. 1992 Apr;45(4):259-65.

PMID:
1603817
35.

Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis.

Reid GK, Kargman S, Vickers PJ, Mancini JA, Léveillé C, Ethier D, Miller DK, Gillard JW, Dixon RA, Evans JF.

J Biol Chem. 1990 Nov 15;265(32):19818-23.

36.

Urinary leukotriene E4 levels during early and late asthmatic responses.

Manning PJ, Rokach J, Malo JL, Ethier D, Cartier A, Girard Y, Charleson S, O'Byrne PM.

J Allergy Clin Immunol. 1990 Aug;86(2):211-20.

PMID:
2166758
37.

BIO-Fully Automated Sample Treatment high-performance liquid chromatography and radioimmunoassay for leukotriene E4 in human urine from asthmatics.

Nicoll-Griffith D, Zamboni R, Rasmussen JB, Ethier D, Charleson S, Tagari P.

J Chromatogr. 1990 Apr 6;526(2):341-54.

PMID:
2163406
38.

Application of reversed phase high performance liquid chromatography to the analysis of sulphidopeptide leukotrienes in pig bile.

Tagari P, Ethier D, Ford-Hutchinson A, Cirino M.

Biomed Chromatogr. 1990 Jan;4(1):39-42.

PMID:
2310841
39.

Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay.

Tagari P, Ethier D, Carry M, Korley V, Charleson S, Girard Y, Zamboni R.

Clin Chem. 1989 Mar;35(3):388-91.

40.

Tetrahydrocarbazol-1-acetic acids: new class of thromboxane receptor antagonists.

Girard Y, Yoakim-Rancourt C, Hamel P, Gillard JW, Guindon Y, Letts G, Evans J, Léveillé C, Ethier D, Lord A, et al.

Prog Clin Biol Res. 1989;301:585-9. No abstract available.

PMID:
2529558
41.

The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor.

Gillard JW, Morton HE, Fortin R, Yoakim C, Girard Y, Lord A, Ethier D, Leveille C, Letts G, Evans J, et al.

Prog Clin Biol Res. 1989;301:579-83. No abstract available.

PMID:
2529557
42.

L-641,953 (R-8-fluoro-dibenzo[b, f]thiepin-3-carboxylic acid-5-oxide): a novel thromboxane-prostaglandin endoperoxide antagonist.

Hall RA, Rokach JR, Bélanger P, Bianchi L, Ethier D, Ford-Hutchinson AW, Girard Y, Hamel P, Hamel R, Lord A, et al.

Can J Physiol Pharmacol. 1987 Apr;65(4):509-14.

PMID:
3607600
43.

Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist.

Hall RA, Gillard J, Guindon Y, Letts G, Champion E, Ethier D, Evans J, Ford-Hutchinson AW, Fortin R, Jones TR, et al.

Eur J Pharmacol. 1987 Mar 17;135(2):193-201.

PMID:
3582493
44.

L-648,051: an aerosol active leukotriene D4 receptor antagonist.

Jones TR, Guindon Y, Champion E, Charette L, DeHaven RN, Denis D, Ethier D, Ford-Hutchinson AW, Fortin R, Frenette R, et al.

Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:1012-7. No abstract available.

PMID:
2823551
45.

L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)- propylsulfonyl]-gamma-oxo-benzenebutanoate: a leukotriene D4 receptor antagonist.

Jones TR, Guindon Y, Young R, Champion E, Charette L, Denis D, Ethier D, Hamel R, Ford-Hutchinson AW, Fortin R, et al.

Can J Physiol Pharmacol. 1986 Dec;64(12):1535-42.

PMID:
3030524
46.

Studies on L-640,035: a novel antagonist of contractile prostanoids in the lung.

Carrier R, Cragoe EJ, Ethier D, Ford-Hutchinson AW, Girard Y, Hall RA, Hamel P, Rokach J, Share NN, Stone CA, et al.

Br J Pharmacol. 1984 Jun;82(2):389-95.

47.

Supplemental Content

Loading ...
Support Center